الرئيسية » أخبار

أخبار

Thalassaemia Prior and Consequent to COVID-19 Pandemic: The Perspective of Thalassaemia International Federation (TIF)

  Patients with haemoglobin disorders, particularly β-thalassaemia or sickle cell disease (SCD) or combined forms, on account of their underlying disease pathology and associated (iron load mainly in the case of thalassaemia) co-morbidities, are defined as high-risk individuals, prone to develop more severe complications from SARS-COV-2. Despite the fact that ...

أكمل القراءة »

Gene Therapy & Thalassaemia Version 2.3: A TIF Survey

Millions of people worldwide suffer from inherited non-malignant blood disorders like thalassaemia and sickle cell disease. The culprit: genetic defects in their blood stem cells. One of the novel therapies  for thalassaemia that has stood out recently has undoubtedly been the first and only, one-time, groundbreaking gene therapy for transfusion ...

أكمل القراءة »

European Commission Approves Reblozyl for the Treatment of Transfusion-dependent β-Thalassaemia

Reblozyl’s long-awaited approval in Europe has finally arrived! Bristol Myers Squibb (BMS) & Acceleron Pharma announced today that the European Commission approved Reblozyl (luspatercept) for the treatment of Transfusion-Dependent β-#Thalassaemia (TDT) in adult patients. Reblozyl has the potential to address the ineffective erythropoiesis associated with β-thalassaemia and MDS, decrease patients’ dependence ...

أكمل القراءة »

TIF and Hemanext® Inc. Announce New Strategic Alliance

TIF, a worldwide organization dedicated to ensuring equal access to quality healthcare for every patient with thalassaemia and other haemoglobin disorders across the world, and Hemanext Inc., a privately held medical technology company dedicated to improving patients’ quality of life by delivering a better red blood cell (RBC) replacement therapy, ...

أكمل القراءة »